Amgen
13
248M
11
0.31
4
0.15
5
- Areas of investment
Summary
Amgen appeared to be the Corporate Investor, which was created in 1980. The company was established in North America in United States. The main department of described Corporate Investor is located in the Thousand Oaks.
The fund is constantly included in 2-6 deals per year. The top amount of exits for fund were in 2010. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. Considering the real fund results, this Corporate Investor is 37 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Amgen performs on 15 percentage points less the average number of lead investments. The common things for fund are deals in the range of more than 100 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Amgen, startups are often financed by dievini Hopp Biotech Holding, Wellington Partners, AT Impf. The meaningful sponsors for the fund in investment in the same round are dievini Hopp Biotech Holding, Z Investments, Wellington Partners. In the next rounds fund is usually obtained by dievini Hopp Biotech Holding, Y Combinator, Wellington Partners.
Among the most popular fund investment industries, there are Medical, Manufacturing. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Oxford Nanopore Technologies, Unilife Corporation, Darmiyan. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Besides them, we counted 4 critical employees of this fund in our database.
Investments analytics
Analytics
- Total investments
- 13
- Lead investments
- 4
- Exits
- 5
- Rounds per year
- 0.31
- Follow on index
- 0.15
- Investments by industry
- Biotechnology (10)
- Health Care (8)
- Medical (7)
- Health Diagnostics (4)
- Therapeutics (3) Show 17 more
- Investments by region
-
- China (1)
- United States (8)
- Germany (2)
- United Kingdom (1)
- Israel (1)
- Peak activity year
- 2017
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 301M
- Group Appearance index
- 0.54
- Avg. company exit year
- 22
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Neumora Therapeutics | 11 Oct 2022 | Biotechnology, Health Care, Medical | Early Stage Venture | 112M | United States, Massachusetts, Watertown |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.